Discovering breakthroughs in fibrosis and neurodegeneration
Blade Therapeutics is advancing a robust pipeline of potential first-in-class, oral, small-molecule therapies for diseases that result from protein deposition (fibrosis) or protein aggregation (neurodegeneration) that disrupt normal cellular, tissue or organ function. This pipeline includes an autotaxin inhibitor and multiple inhibitors of dimeric calpains to treat lung, liver and cardiac fibrosis or neurodegenerative diseases. Since the company’s founding in 2015, Blade has used a combination of in-house drug research and selective in-licensing to build a risk-diversified pipeline.
Our focused approach offers tremendous opportunity to produce disease-modifying, life-saving therapies.
1 Autotaxin Inhibitor
2 Calpain Inhibitor
Calpain 9 as a therapeutic target in TGFβ-induced mesenchymal transition and fibrosis
Kim et al., Sci. Transl. Med. 11, July 2019
Calpain 1 and 2 Are Required for RNA Replication of Echovirus 1
Upla et al., Journal of Virology 82, Feb 2008